Board of Directors

Toby Wilson Waterworth(BSc (Econ), BFP, FCA)

Chief Executive Officer

Toby is a strategic leader and healthcare entrepreneur with a track record of founding and building successful private and listed companies. This includes senior roles at Chiroscience Group plc (LSE) (acquired by Celltech Group plc (LSE) for $535m), Alizyme plc (AIM & LSE at a value of $340m), Expedeon (acquired by Sygnis AG) and Lipoxen plc ($24m AIM IPO and U.S. reverse merger).

Toby is a Fellow of the Institute of Chartered Accountants in England and Wales, Fellow of the Royal Society of Medicine, founder of the UK chapter of MIT Enterprise Forum and former advisor to the UK government in the development and commercialisation of healthcare innovations.

Allan Cambridge(BSc., B. Pharmacy)

Interim Chairman and Non-Executive Director

Allan is a pharmaceutical professional with a 40 year career covering board, CEO and senior leadership roles.

Notable were positions at Evans Medical (GSK) (acquired by Medeva/UCB), Wyeth Laboratories (acquired by Pfizer), Lipoxen Technologies, now Xenetic Biosciences, Inc (NASDAQ:XBIO) and gastroenterology companies Alizyme and Tillotts Pharma (part of Zeria Group, Japan).

In addition, whilst at Deloitte and Touche, Allan advised Du Pont Merck on establishing its European business and the European Commission on establishing the European Medicines Agency (EMA). He was a Board member of the Association of British Pharmaceutical Companies and one of the founding directors of Atlantic Healthcare.

Charles Woler(MD, PhD)

Non-Executive Director

Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies and smaller, earlier stage companies.

He currently holds non-executive Chairman and non-executive Director positions in Europe and the U.S..

Previously Charles was Chairman and CEO of Roche France, Chairman of SmithKline Beecham’s European pharmaceutical business (UK), CEO of Cadus Pharmaceuticals (U.S.) and CEO of Biomnis (France).

Andrew Boyce

Non-Executive Director

Since 1987, Andrew has managed a private family office, which has diverse commercial interests including technology and medical investments, property, and farming. Andrew represents a significant shareholding in Atlantic Healthcare for the family office, and was one of the founding investors in 2006. He is a member of the board of UK AIM-listed Hardide plc, a novel chemicals and coatings technology company, where he has served as a non-executive director since June 2012.

William Ringo(MBA)

Board Advisor

Bill is an eminent pharma veteran with nearly 30 years experience of public markets, M&A, product commercialisation, and financial institutions.

He is currently Chairman of Assembly Biosciences Inc., and a director of Sangamo Therapeutics Inc., Immune Design Corp., Dermira Inc., and Five Prime Therapeutics Inc..

Previous roles include Chairman, CEO and President of NASDAQ-listed InterMune, Inc; SVP of Strategy and Business Development at Pfizer, Inc.; President and CEO of NASDAQ-listed Abgenix, Inc. Bill was also a member of Eli Lilly and Company’s operating committee.